Monday, May 22, 2023 Daily Archives

AstraZeneca ups gene editing capabilities with Revvity deal

by

Revvity will license its Pin-point gene editing platform to AstraZeneca to develop cell therapies for the treatment of immune-meditated diseases and cancer. The non-exclusive agreement, of which financial details have not been divulged, will focus on Revvity’s Pin-Point base editing system as well as its underlying technology. Through gaining access to this gene editing technology, AstraZenca aims to advance its work in the cell therapy space. According to Revvity, its Pin-point system is different to other base editing systems in…

May 22, 2023

IP will encourage investment in capacity needed for next pandemic

by

Intellectual property rules will encourage drug and vaccine firms to invest in the production capacity needed during future pandemics, according to industry group IFPMA. The industry group stressed the need for “robust” IP laws in a statement issued earlier this month, arguing access to vaccines and medical countermeasures is in part determined by developers’ willingness to invest in local manufacturing capacity. “Fostering sustainable manufacturing globally that can scale-up for high volume supply in future pandemics. The right enabling environment to…

May 22, 2023

Catalent limiting CAPEX as part of cost reduction plan

by

Ongoing CAPEX projects will cost $550 million but only the most critical projects will be funded going forward as Catalent attempts to put out financial and operational fires. Amid numerous internal issues, contract development and manufacturing organization (CDMO) Catalent delayed its third quarter fiscal year 2023 financials for a third time and instead provided a business update Friday. “This is not at all the call we expected to have now, and we are not at all where we expected to…

May 22, 2023

Krystal clear: FDA approves redosable gene therapy gel Vyjuvek

by

Krystal Biotech has won approval for Vyjuvek (beremagene geperpavec), a topical gel gene therapy to treat the skin condition dystrophic epidermolysis bullosa (DEB). The handful of gene therapies on the market are single-dose injections or infusions, but the US Food and Drug Administration (FDA) approved the first ‘redosable’ gene therapy Friday, in the form of Krystal’s Vyjuvek. Vyjuvek is a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, which when administered topically to DEB wounds delivers two copies of the…

May 22, 2023